|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Endocrinology,3 Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, Ohio 45229-3039
Université Paris Descartes,4 Faculté de Médecine René Descartes 5 site Necker, 75015 Paris, France
INSERM,5 Unit 808, Laboratory of PRL, GH and Tumors, 75730 Paris Cedex 15, France
ABSTRACT
Human prolactin (PRL) and its receptor (PRLR) are markedly induced during human uterine decidualization, and large amounts of PRL are released by decidual cells as differentiation progresses. However, the role of PRL in decidualization is unknown. In order to determine whether PRL plays an autocrine role in decidualization, human uterine fibroblast cells that were decidualized in vitro with medroxyprogestrerone acetate (1 µM), estradiol (10 nM), and prostaglandin E2 (1 µM) were exposed to exogenous PRL and/or the pure PRLR antagonist delta1–9-G129R-PRL. As measured by quantitative PCR, cells that were decidualized in the presence of exogenous PRL (0.25–2 µg/ml) expressed significantly lower levels of mRNA for the genes that encode insulin-like growth factor binding protein 1 (IGFBP1), left-right determination factor 2 (LEFTY2), PRL, decorin (DCN), and laminin alpha 1 (LAMA1), all of which are known to be induced during decidualization. These effects were blocked when the cells were exposed simultaneously to PRL and the PRLR antagonist, which confirms the specific inhibitory action of PRL on the expression of decidualization markers. In addition, cells exposed to the PRLR antagonist alone expressed higher levels of the marker gene mRNAs than cells that were decidualized in control media. Taken together, these results strongly suggest that PRL acts via an autocrine mechanism to regulate negatively the extent of differentiation (decidualization) of human uterine cells.
decidua, prolactin, prolactin receptor
1Supported by grant HD-15201 from the National Institutes of Health.
Correspondence: 2Stuart Handwerger, Cincinnati Children's Hospital Medical Center, Division of Endocrinology, MLC 7012, 3333 Burnet Avenue, Cincinnati, OH 45229-3039. FAX: 513 636 7486; e-mail: stuart.handwerger{at}cchmc.org
This article has been cited by other articles:
![]() |
H. P. Gaide Chevronnay, P. B. Cornet, D. Delvaux, P. Lemoine, P. J. Courtoy, P. Henriet, and E. Marbaix Opposite Regulation of Transforming Growth Factors-{beta}2 and -{beta}3 Expression in the Human Endometrium Endocrinology, March 1, 2008; 149(3): 1015 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Minici, F. Tiberi, A. Tropea, M. Orlando, M. F. Gangale, F. Romani, S. Campo, A. Bompiani, A. Lanzone, and R. Apa Endometriosis and human infertility: a new investigation into the role of eutopic endometrium Hum. Reprod., March 1, 2008; 23(3): 530 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-B. Jomain, E. Tallet, I. Broutin, S. Hoos, J. van Agthoven, A. Ducruix, P. A. Kelly, B. B. Kragelund, P. England, and V. Goffin Structural and Thermodynamic Bases for the Design of Pure Prolactin Receptor Antagonists: X-RAY STRUCTURE OF Del1-9-G129R-hPRL J. Biol. Chem., November 9, 2007; 282(45): 33118 - 33131. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |